Answer
Rifampicin is contraindicated with Symtuza because its CYP3A induction can lower darunavir and cobicistat concentrations, potentially causing loss of therapeutic effect; the contraindications also list a risk of serious and/or life-threatening adverse reactions.
Sources for this answer
- Symtuza 800 mg/150 mg/200 mg/10 mg film coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.5 Interaction with other medicinal products · Version 17Document updated
- Symtuza 800 mg/150 mg/200 mg/10 mg film coated tablets